down arrow

Eyenovia, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30234E1047
USD
3.97
0.06 (1.53%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.504.09

52 Week

0.8517.99
Valuation
Technical
Day's Volume

CASH

408.63 k

Shareholding (Mar 2025)

FII

9.65%

Held by 15 FIIs

DII

87.67%

Held by 3 DIIs

Promoter

0.00%

How big is Eyenovia, Inc.?

22-Jun-2025

As of Jun 18, Eyenovia, Inc. has a market capitalization of 20.09 million, with net sales of 0.06 million and a net profit of -42.37 million over the last four quarters. Shareholder's funds are reported at -13.10 million, and total assets amount to 3.67 million.

As of Jun 18, Eyenovia, Inc. has a market capitalization of 20.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.06 million, while the sum of net profit for the same period is -42.37 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -13.10 million, and total assets amount to 3.67 million.

Read More

What does Eyenovia, Inc. do?

22-Jun-2025

Eyenovia, Inc. is a clinical stage biopharmaceutical company focused on developing micro-dose therapeutics. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $20.09 million.

Overview: <BR>Eyenovia, Inc. is a clinical stage biopharmaceutical company engaged in developing micro-dose therapeutics products in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 20.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.68 <BR>Return on Equity: 305.10% <BR>Price to Book: -2.07<BR><BR>Contact Details: <BR>Address: 295 Madison Ave Ste 2400, NEW YORK NY: 10017 <BR>Tel: ['1 813 7669539', '1 646 5367035'] <BR>Fax: 1 302 6365454 <BR>Website: https://eyenoviabio.com/

Read More

Who are in the management team of Eyenovia, Inc.?

22-Jun-2025

As of March 2022, the management team of Eyenovia, Inc. includes Dr. Fredric Eshelman (Independent Chairman), Dr. Tsontcho Ianchulev (CEO, Director, Chief Medical Officer), and several Independent Directors: Dr. Curt Labelle, Mr. Kenneth Lee, Dr. Ernest Mario, Mr. Charles Mather, and Dr. Anthony Sun. This team oversees the company's strategic direction and operations.

As of March 2022, the management team of Eyenovia, Inc. includes the following individuals:<BR><BR>- Dr. Fredric Eshelman, who serves as the Independent Chairman of the Board.<BR>- Dr. Tsontcho Ianchulev, who is the Chief Executive Officer, Director, and Chief Medical Officer.<BR>- Dr. Curt Labelle, who is a Director.<BR>- Mr. Kenneth Lee, who is an Independent Director.<BR>- Dr. Ernest Mario, who is also an Independent Director.<BR>- Mr. Charles Mather, who serves as an Independent Director.<BR>- Dr. Anthony Sun, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Eyenovia, Inc. overvalued or undervalued?

25-Jun-2025

As of March 30, 2023, Eyenovia, Inc. is considered overvalued with negative financial metrics, including a price-to-book value of -1.45 and an EV to EBITDA of -0.78, and has underperformed significantly with a year-to-date return of -53.08%.

As of 30 March 2023, Eyenovia, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued, particularly given its negative financial metrics. Key ratios include a price-to-book value of -1.45, an EV to EBIT of -0.75, and an EV to EBITDA of -0.78, all indicating significant financial distress.<BR><BR>In comparison to its peers, Eyenovia's EV to EBITDA ratio of -0.75 is notably higher than G1 Therapeutics, Inc. at -9.6487 and ADC Therapeutics SA at -4.8904, both of which are classified as risky. The stark contrast in valuation metrics suggests that Eyenovia is not only struggling financially but also lacks the fundamentals to justify its current price of 5.48. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -53.08%, significantly underperforming the S&P 500's 2.44% return.

Read More

Is Eyenovia, Inc. technically bullish or bearish?

20-Sep-2025

As of August 11, 2025, Eyenovia, Inc. shows a mildly bullish trend driven by daily moving averages and the weekly MACD, despite mixed signals from the RSI and longer-term performance underwhelming compared to the S&P 500.

As of 11 August 2025, the technical trend for Eyenovia, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and both the KST and Dow Theory show bearish signals on a monthly basis. The Bollinger Bands reflect a mildly bullish trend weekly but mildly bearish monthly. <BR><BR>In terms of performance, Eyenovia has outperformed the S&P 500 over the past week and month, with returns of 2.42% and 64.61% respectively, but has significantly underperformed over the longer term, with a 1-year return of -69.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly MACD.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

-77.36%

stock-summary
Price to Book

0.99

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-32.48%
0%
-32.48%
6 Months
88.15%
0%
88.15%
1 Year
-46.0%
0%
-46.0%
2 Years
-96.53%
0%
-96.53%
3 Years
103.07%
0%
103.07%
4 Years
-98.58%
0%
-98.58%
5 Years
-98.63%
0%
-98.63%

Eyenovia, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Eyenovia, Inc. technically bullish or bearish?

As of 11 August 2025, the technical trend for Eyenovia, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance. However, the weekly RSI is bearish, and both the KST and Dow Theory show bearish signals on a monthly basis. The Bollinger Bands reflect a mildly bullish trend weekly but mildly bearish monthly. In terms of performance, Eyenovia has outperformed the S&P 500 over the past week and month, with returns of 2.42% and 64.61% respectively, but has significantly underperformed over the longer term, with a 1-year return of -69.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and the weekly MACD....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.79%
EBIT Growth (5y)
-7.34%
EBIT to Interest (avg)
-14.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.68
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
22.58%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.45
EV to EBIT
-0.75
EV to EBITDA
-0.78
EV to Capital Employed
-6.72
EV to Sales
20.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 14 Schemes (2.68%)

Foreign Institutions

Held by 15 Foreign Institutions (9.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 21.62% vs -79.03% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-8.50",
          "chgp": "2.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.70",
          "chgp": "-28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.70",
          "val2": "-11.10",
          "chgp": "21.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-389,999.70%",
          "chgp": "38,999.97%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -82.42% vs 2.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.50",
          "val2": "-24.60",
          "chgp": "-28.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "2.40",
          "chgp": "4.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.80",
          "val2": "-27.30",
          "chgp": "-82.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-569,724.60%",
          "val2": "-6,708,858.20%",
          "chgp": "6,13,913.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-8.30
-8.50
2.35%
Interest
0.50
0.70
-28.57%
Exceptional Items
0.00
-1.60
100.00%
Consolidate Net Profit
-8.70
-11.10
21.62%
Operating Profit Margin (Excl OI)
0.00%
-389,999.70%
38,999.97%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 21.62% vs -79.03% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.00
Operating Profit (PBDIT) excl Other Income
-31.50
-24.60
-28.05%
Interest
2.50
2.40
4.17%
Exceptional Items
-14.80
0.00
Consolidate Net Profit
-49.80
-27.30
-82.42%
Operating Profit Margin (Excl OI)
-569,724.60%
-6,708,858.20%
6,13,913.36%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -82.42% vs 2.50% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Eyenovia, Inc. stock-summary
stock-summary
Eyenovia, Inc.
Pharmaceuticals & Biotechnology
Eyenovia, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of micro-doses therapeutics products utilizing the patented piezo-print delivery technology. Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for mydriasis, myopia progression, glaucoma, and other eye diseases. MicroStat is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is topical treatment for progressive myopia, a back-of-the-eye disease. MicroProst is latanoprost formulation product candidate, which is being developed for the reduction of IOP in patients with Chronic Angle Closure Glaucoma (CACG), as well as Primary Open Angle Glaucoma (POAG) and Ocular Hypertension. MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product.
Company Coordinates stock-summary
Company Details
295 Madison Ave Ste 2400 , NEW YORK NY : 10017
stock-summary
Tel: 1 813 76695391 646 5367035
stock-summary
https://eyenoviabio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."